| Michael Chang, MD | |
|
441 N Lakeview Ave, Anaheim, CA 92807-3028 | |
| (888) 988-2800 | |
| Not Available |
| Full Name | Michael Chang |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 441 N Lakeview Ave, Anaheim, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790985372 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | A93146 (California) | Primary |
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
Mayo Clinic epidemiologists have found that the systemic inflammation characterizing rheumatoid arthritis may be to blame for the increased risk of cardiovascular death in patients with the disease.
The Food and Drug Administration (FDA) has approved Tyzeka (telbivudine) for the treatment of adults with chronic hepatitis B (HBV), a serious viral infection that attacks the liver and can cause lifelong infection, scarring of the liver (cirrhosis), and eventually liver cancer, liver failure, and death.
A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.
DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe, was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer.
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Chang, MD 441 N Lakeview Ave, Anaheim, CA 92807-3028 Ph: (888) 988-2800 | Michael Chang, MD 441 N Lakeview Ave, Anaheim, CA 92807-3028 Ph: (888) 988-2800 |
News Archive
Mayo Clinic epidemiologists have found that the systemic inflammation characterizing rheumatoid arthritis may be to blame for the increased risk of cardiovascular death in patients with the disease.
The Food and Drug Administration (FDA) has approved Tyzeka (telbivudine) for the treatment of adults with chronic hepatitis B (HBV), a serious viral infection that attacks the liver and can cause lifelong infection, scarring of the liver (cirrhosis), and eventually liver cancer, liver failure, and death.
A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.
DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe, was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer.
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.
› Verified 8 days ago
Ritu Khurana Rawal, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Darren Murtari, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Jennifer Linzmeyer, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 714-279-4567 Fax: 714-278-5908 | |
Geman Cheng, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
David J. Cordes, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Ya-mei T. Yu, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Kirtine Lee Yang, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 500 S Anaheim Hills Rd Ste 110, Anaheim, CA 92807 Phone: 714-282-2229 Fax: 877-794-9299 |